MCID: FML037
MIFTS: 52

Female Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Female Breast Cancer

MalaCards integrated aliases for Female Breast Cancer:

Name: Female Breast Cancer 12 14
Female Breast Carcinoma 12 14 69
Malignant Neoplasm of Female Breast 69
Mammary Carcinoma of Female Breast 12
Carcinoma of Female Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050671 DOID:7843
NCIt 46 C2918

Summaries for Female Breast Cancer

Disease Ontology : 12 A breast carcinoma that is manifested in the female breast.

MalaCards based summary : Female Breast Cancer, also known as female breast carcinoma, is related to breast cancer and endometrium carcinoma in situ. An important gene associated with Female Breast Cancer is PGR (Progesterone Receptor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Cyclophosphamide and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Female Breast Cancer

Diseases related to Female Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 breast cancer 26.6 AR ATM BRCA2 CYP1A1 ERBB2 ESR1
2 endometrium carcinoma in situ 10.5 PGR TP53
3 nosophobia 10.5 BRCA2 PGR
4 cancerophobia 10.5 BRCA2 PGR
5 scirrhous adenocarcinoma 10.5 ERBB2 PGR
6 breast apocrine carcinoma 10.5 ERBB2 PGR
7 female reproductive endometrioid cancer 10.5 PGR TP53
8 vulvar syringoma 10.5 ESR1 PGR
9 breast malignant phyllodes tumor 10.5 PGR TP53
10 tetraploidy 10.5 BRCA2 TP53
11 lung leiomyoma 10.5 ESR1 PGR
12 tuberculous salpingitis 10.5 BRCA2 ERBB2
13 olfactory groove meningioma 10.5 PGR TP53
14 intracystic papillary adenoma 10.5 ERBB2 PGR
15 progesterone-receptor negative breast cancer 10.5 ERBB2 PGR
16 vulvar benign neoplasm 10.5 ESR1 PGR
17 trigonitis 10.5 ESR1 PGR
18 vulvar leiomyoma 10.5 ESR1 PGR
19 endometrial clear cell adenocarcinoma 10.5 ESR1 TP53
20 chordoid glioma 10.5 PGR TP53
21 predominantly cortical thymoma 10.5 ESR1 PGR
22 tracheoesophageal fistula with or without esophageal atresia 10.5 BRCA2 PALB2
23 glioma susceptibility 1 10.5 ERBB2 TP53
24 papillary serous adenocarcinoma 10.5 PGR TP53
25 progesterone resistance 10.5 ESR1 PGR
26 cribriform carcinoma 10.4 ESR1 PGR
27 gastric signet ring cell adenocarcinoma 10.4 ESR1 PGR
28 non-proliferative fibrocystic change of the breast 10.4 ERBB2 TP53
29 endometrial mucinous adenocarcinoma 10.4 ESR1 PGR
30 bap1 tumor predisposition syndrome 10.4 BRCA2 PALB2
31 anterior cranial fossa meningioma 10.4 PGR TP53
32 adenoid basal cell carcinoma 10.4 ESR1 PGR
33 deep angioma 10.4 ESR1 PGR
34 breast squamous cell carcinoma 10.4 ERBB2 PGR
35 comedo carcinoma 10.4 ERBB2 ESR1
36 pleomorphic adenoma carcinoma 10.4 ERBB2 TP53
37 intramuscular hemangioma 10.4 ESR1 PGR
38 estrogen excess 10.4 ESR1 PGR
39 oral leukoplakia 10.4 ERBB2 TP53
40 bartholin's duct cyst 10.4 AR TP53
41 retinitis pigmentosa 47 10.4 ESR1 PGR
42 tumor predisposition syndrome 10.4 BRCA2 PALB2
43 adenomyosis 10.3 ESR1 PGR
44 corneal abscess 10.3 AR PGR
45 uterine body mixed cancer 10.3 ERBB2 PGR TP53
46 microglandular adenosis 10.3 ERBB2 PGR TP53
47 vestibular gland benign neoplasm 10.3 ESR1 PGR TP53
48 uterine corpus serous adenocarcinoma 10.3 BRCA2 ERBB2 TP53
49 bartholin's gland adenoma 10.3 ESR1 PGR TP53
50 retinitis pigmentosa 20 10.3 ESR1 PGR

Comorbidity relations with Female Breast Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Breast Fibroadenosis
Deficiency Anemia Fat Necrosis of Breast
Hypertension, Essential Hypothyroidism
Mastitis Microglandular Adenosis
Neutropenia

Graphical network of the top 20 diseases related to Female Breast Cancer:



Diseases related to Female Breast Cancer

Symptoms & Phenotypes for Female Breast Cancer

GenomeRNAi Phenotypes related to Female Breast Cancer according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 ATM BRCA2 ERCC4 PALB2 TOP2A TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 TP53 ATM BRCA2 ERCC4 PALB2 TOP2A
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BRCA2 ERCC4 PALB2 TOP2A TP53

MGI Mouse Phenotypes related to Female Breast Cancer:

43 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.15 PGR TP53 AR ATM BRCA2 ERBB2
2 growth/size/body region MP:0005378 10.13 AR ATM BRCA2 CYP1A1 ERBB2 ERCC4
3 cardiovascular system MP:0005385 10.11 AR ATM CYP1A1 ERBB2 ESR1 PALB2
4 endocrine/exocrine gland MP:0005379 10.11 AR ATM BRCA2 CYP1A1 ERBB2 ESR1
5 homeostasis/metabolism MP:0005376 10.1 AR ATM BRCA2 CYP1A1 ERBB2 ESR1
6 embryo MP:0005380 10.08 AR ATM BRCA2 ERBB2 ESR1 PALB2
7 mortality/aging MP:0010768 10.03 AR ATM BRCA2 CYP1A1 ERBB2 ERCC4
8 integument MP:0010771 10.02 AR ATM BRCA2 ERBB2 ESR1 PALB2
9 limbs/digits/tail MP:0005371 9.87 AR BRCA2 ERBB2 ESR1 PALB2 PGR
10 neoplasm MP:0002006 9.76 AR ATM BRCA2 ERBB2 ESR1 PALB2
11 normal MP:0002873 9.5 AR BRCA2 CYP1A1 ERBB2 ESR1 PGR
12 reproductive system MP:0005389 9.23 PHB TP53 ERBB2 ESR1 PGR AR

Drugs & Therapeutics for Female Breast Cancer

Drugs for Female Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 189)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3 23214-92-8 31703
3
Epirubicin Approved Phase 4,Phase 3,Phase 1,Phase 2 56420-45-2 41867
4
Fluorouracil Approved Phase 4,Phase 3 51-21-8 3385
5
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2 112809-51-5 3902
6
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
7
Toremifene Approved, Investigational Phase 4,Phase 3 89778-26-7 3005573
8
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2 38396-39-3, 2180-92-9 2474
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 437-38-7 3345
10
Morphine Approved, Investigational Phase 4 57-27-2 5288826
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Methylene blue Approved, Investigational Phase 4 61-73-4
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3 31703
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
21 Aromatase Inhibitors Phase 4,Phase 3,Phase 2
22 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2
23 Estrogen Antagonists Phase 4,Phase 3,Phase 2
24 Estrogens Phase 4,Phase 3,Phase 2
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
26 Hormones Phase 4,Phase 3,Phase 2,Early Phase 1
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Early Phase 1
28 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
31 Estrogen Receptor Modulators Phase 4,Phase 3
32 Selective Estrogen Receptor Modulators Phase 4,Phase 3
33 Anesthetics Phase 4,Phase 3,Phase 2
34 Anesthetics, Local Phase 4,Phase 3,Phase 2
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
36 Adjuvants, Anesthesia Phase 4,Phase 2
37 Analgesics Phase 4,Phase 3,Phase 2
38 Analgesics, Opioid Phase 4,Phase 2
39 Anesthetics, General Phase 4,Phase 2
40 Anesthetics, Intravenous Phase 4,Phase 2
41 Narcotics Phase 4,Phase 2
42 Anesthetics, Inhalation Phase 4
43 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2
44 Platelet Aggregation Inhibitors Phase 4
45 Calcium, Dietary Phase 4,Phase 2,Early Phase 1
46 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2
48 Cyclooxygenase Inhibitors Phase 4,Phase 2
49
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
50
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3

Interventional clinical trials:

(show top 50) (show all 138)

# Name Status NCT ID Phase Drugs
1 A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging Unknown status NCT00531973 Phase 4 liposomal doxorubicin;epirubicin
2 Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer Recruiting NCT02089854 Phase 4 Toremifene; Anastrozole
3 PEMF and PEC Blocks in Mastectomy Reconstruction Patients Recruiting NCT03360214 Phase 4 Bupivacaine Hydrochloride
4 Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy Recruiting NCT03051503 Phase 4 The Transdermal Therapeutic System-Fentanyl (TTS-F)
5 Anesthesia and Circulating Tumor Cells in Breast Cancer Recruiting NCT02005770 Phase 4 Sevoflurane;Propofol
6 Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients Recruiting NCT02982148 Phase 4
7 HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer Not yet recruiting NCT03111615 Phase 4 Aromatase Inhibitors
8 Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn Withdrawn NCT03007381 Phase 4 Ketorolac Tromethamine;Normal Saline
9 Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients. Completed NCT03381417 Phase 3 pegcyte;Neulastim
10 Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer Completed NCT02980965 Phase 3 letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel;fluorouracil, epirubicin, cyclophosphamide, docetaxel
11 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
12 A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
13 Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer Recruiting NCT03351062 Phase 3 Tamoxifen;Toremifene
14 Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate Recruiting NCT02600923 Phase 3 Palbociclib;Letrozole
15 Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Active, not recruiting NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
16 Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block Not yet recruiting NCT03063073 Phase 3 Dexmedetomidine Injection [Precedex];Bupivacaine
17 A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer Not yet recruiting NCT03403712 Phase 3 fosnetupitant/ palonosetron;netupitant/palonosetron;dexamethasone
18 Iron Supplement in the Prevention of Anemia in Female Breast Cancer Patients Unknown status NCT01168505 Phase 2 ferric hydroxide saccharate
19 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction Completed NCT01466270 Phase 2 donepezil hydrochloride;Placebo
20 Treatment for Patients Suffering From Anemia Due to Chemotherapy Completed NCT00120692 Phase 2 Darbepoetin Alfa;Recombinant Human Erythropoietin
21 Dose Dense TC + Pegfilgrastim Support for Breast Cancer Completed NCT01671319 Phase 2 docetaxel + cyclophosphamide + pegfilgrastim
22 Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Completed NCT01204125 Phase 2 paclitaxel;Iniparib (SAR2405550 -BSI-201)
23 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy Completed NCT01091974 Phase 2 armodafinil;Placebo Comparator
24 Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy Completed NCT02527746 Phase 1, Phase 2 EC regimen
25 The HEALS Project - Health Education and Active Living for Surviving Seniors Completed NCT01305044 Phase 2
26 Immunogenicity and Safety of DCs in Breast Cancer Recruiting NCT03450044 Phase 1, Phase 2
27 Tissue Stresses of Cancer (Force Horizon 2020) Recruiting NCT03238144 Phase 1, Phase 2
28 Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA) Recruiting NCT03065621 Phase 2 Palbociclib
29 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer Recruiting NCT02942355 Phase 2 anastrozole;Palbociclib
30 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant Recruiting NCT02540330 Phase 2 Fulvestrant
31 Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients Recruiting NCT03342417 Phase 2
32 PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery Recruiting NCT03084536 Phase 2 Bupivacaine;Gabapentin;Celecoxib;Acetaminophen;Midazolam;Fentanyl
33 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Recruiting NCT03112590 Phase 1, Phase 2 Paclitaxel;Trastuzumab
34 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery Recruiting NCT03113825 Phase 2 AVB-620
35 Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer Recruiting NCT03384914 Phase 2
36 Denosumab as an add-on Neoadjuvant Treatment (GeparX) Recruiting NCT02682693 Phase 2 Denosumab;nab-Paclitaxel;Epirubicin;Cyclophosphamide;Carboplatin;Trastuzumab;Pertuzumab
37 Phase II Trial for Large ER-Negative Breast Cancers Active, not recruiting NCT01869192 Phase 2 Epirubicin;Cyclophosphamide;Docetaxel;Capecitabine
38 Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine Active, not recruiting NCT01654068 Phase 2
39 Study on Androgen Receptor and Triple Negative Breast Cancer Not yet recruiting NCT03383679 Phase 2 Darolutamide;Capecitabine
40 Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab Not yet recruiting NCT03328026 Phase 1, Phase 2 Low dose cyclophosphamide
41 Effect of Methylphenidate on Cancer-related Cognitive Impairment Not yet recruiting NCT02970500 Phase 2 Methylphenidate HCl 10Mg SR;Placebo Comparator
42 Estrogen for Triple Negative Breast Cancer Terminated NCT01083641 Phase 2 Estradiol
43 Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery Withdrawn NCT01612910 Phase 2 oral microencapsulated diindolylmethane
44 Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) Recruiting NCT03109080 Phase 1 Olaparib
45 Treatment Decision Making Between Oncologists and Women With Newly Diagnosed Breast Cancer and Their Healthy Companions Terminated NCT00891969 Phase 1
46 Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance Unknown status NCT00309933
47 Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer Unknown status NCT01542203
48 Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy Unknown status NCT02243163
49 The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes. Unknown status NCT01758419
50 Medical Radiometer - RTM - 01 - RES and Its Use in Detecting Hotspots in Female Breast Unknown status NCT02286583

Search NIH Clinical Center for Female Breast Cancer

Genetic Tests for Female Breast Cancer

Anatomical Context for Female Breast Cancer

MalaCards organs/tissues related to Female Breast Cancer:

38
Breast, Lymph Node, Bone, Thyroid, Prostate, Testes, Whole Blood

Publications for Female Breast Cancer

Articles related to Female Breast Cancer:

(show top 50) (show all 156)
# Title Authors Year
1
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer. ( 29396493 )
2018
2
Acceptability and satisfaction of Project MOVE: a pragmatic feasibility trial aimed at increasing physical activity in female breast cancer survivors. ( 29409128 )
2018
3
Urban rural disparity in female breast cancer incidence rate in China and the increasing trend in parallel with socioeconomic development and urbanization in a rural setting. ( 29280294 )
2018
4
Natural Terpenoids Against Female Breast Cancer: a 5-year Recent Research. ( 29446727 )
2018
5
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer. ( 29098396 )
2018
6
Correction to: Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of Primary Care Physicians (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29294225 )
2018
7
Estimated and Interactively Visualized Female Breast Cancer Incidence Rates in Missouri Senate Districts: 2008-2012. ( 29403576 )
2017
8
Predictors of distress in female breast cancer survivors: a systematic review. ( 28553684 )
2017
9
Evaluation of BRCA1 Large Genomic Rearrangements in Group of Egyptian Female Breast Cancer Patients Using MLPA. ( 29019333 )
2017
10
Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients. ( 29135103 )
2017
11
Marital adjustment in the context of female breast cancer: A systematic review. ( 28342270 )
2017
12
Clinical outcomes of female breast cancer according to BRCA mutation status. ( 28601786 )
2017
13
Dietary Factors and Female Breast Cancer Risk: A Prospective Cohort Study. ( 29215604 )
2017
14
Geographic variations in female breast cancer incidence in relation to ambient air emissions of polycyclic aromatic hydrocarbons. ( 28616736 )
2017
15
Metastasis and its Related Factors in Female Breast Cancer Patients in Kerman, Iran ( 28669169 )
2017
16
Perceptions of Arab men regarding female breast cancer screening examinations-Findings from a Middle East study. ( 28732040 )
2017
17
Depressive symptoms during adverse economic and political circumstances: A comparative study on Greek female breast cancer patients receiving chemotherapy treatment. ( 28398649 )
2017
18
Model-based Recursive Partitioning for Survival of Iranian Female Breast Cancer Patients: Comparing with Parametric Survival Models. ( 28451527 )
2017
19
Female breast cancer management and survival: The experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. ( 28990314 )
2017
20
Male breast cancer: a nation-wide population-based comparison with female breast cancer. ( 29276849 )
2017
21
Trends in Female Breast Cancer by Age Group in the Chiang Mai Population ( 28612595 )
2017
22
Recommendations for the follow-up care of female breast cancer survivors: a guideline of the Spanish Society of Medical Oncology (SEOM), Spanish Society of General Medicine (SEMERGEN), Spanish Society for Family and Community Medicine (SEMFYC), Spanish Society for General and Family Physicians (SEMG), Spanish Society of Obstetrics and Gynecology (SEGO), Spanish Society of Radiation Oncology (SEOR), Spanish Society of Senology and Breast Pathology (SESPM), and Spanish Society of Cardiology (SEC). ( 29139040 )
2017
23
No genetic relationship between TLR2 rs4696480, rs3804100, and rs3804099 gene polymorphisms and female breast cancer in Saudi populations. ( 28490891 )
2017
24
Familial associations of female breast cancer with other cancers. ( 28801919 )
2017
25
Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens. ( 28639031 )
2017
26
No Evaluation of Serum P53 Levels in Iraqi Female Breast Cancer Patients ( 28952299 )
2017
27
Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. ( 28607590 )
2017
28
Exploring neighborhood inequality in female breast cancer incidence in Tehran using Bayesian spatial models and a spatial scan statistic. ( 28774168 )
2017
29
Conditional relative survival among female breast cancer patients in the United States. ( 29063648 )
2017
30
Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients. ( 29183284 )
2017
31
Physical symptoms and working performance in female breast cancer survivors: a systematic review. ( 28325132 )
2017
32
Disparities in Female Breast Cancer Stage at Diagnosis in New Jersey: A Spatial-Temporal Analysis. ( 28430705 )
2017
33
BRIP1/FANCJ Mutation Analysis in a Family with History of Male and Female Breast Cancer in India. ( 28382101 )
2017
34
Predictors of quality of life in Czech female breast cancer survivors following treatment with special interest to coping strategies. ( 28840734 )
2017
35
Province Disparity on Female Breast Cancer in Iran. ( 29259957 )
2017
36
Overview of female breast cancer in northern Tocantins - Brazil. ( 29019533 )
2017
37
Descriptive Epidemiology of Female Breast Cancer in Delhi, India ( 28545200 )
2017
38
Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel Chemotherapy. ( 27064666 )
2016
39
Type 2 Diabetes Mellitus as a Risk Factor for Female Breast Cancer in the Population of Northern Pakistan. ( 27509959 )
2016
40
Relationship between five GWAS-identified single nucleotide polymorphisms and female breast cancer in the Chinese Han population. ( 26803517 )
2016
41
Geographical and Temporal Variations in Female Breast Cancer Mortality in the Municipalities of Andalusia (Southern Spain). ( 27879690 )
2016
42
Comparison of Clinicopathological Features and Treatments between Young (a8o40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study. ( 27031236 )
2016
43
Role of PALB2 Polymorphisms with Regard to Susceptibility to Female Breast Cancer Risk in the Chinese Population. ( 26981788 )
2016
44
Identification of novel serum peptides biomarkers for female breast cancer patients in Western China. ( 26705257 )
2016
45
Geographical Inequalities in Surgical Treatment for Localized Female Breast Cancer, Queensland, Australia 1997-2011: Improvements over Time but Inequalities Remain. ( 27447656 )
2016
46
Incidence rate of female breast cancer in urban Shijiazhuang in 2012 and modifiable risk factors. ( 27766774 )
2016
47
Mutations in Human Interferon I+2b Gene and Potential as Risk Factor Associated with Female Breast Cancer. ( 27403569 )
2016
48
Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis. ( 27460637 )
2016
49
Study on female breast cancer imaging screening consultation network in Guangdong Province, China. ( 27172743 )
2016
50
Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial. ( 27400910 )
2016

Variations for Female Breast Cancer

Expression for Female Breast Cancer

Search GEO for disease gene expression data for Female Breast Cancer.

Pathways for Female Breast Cancer

Pathways related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 AR ATM BRCA2 ERBB2 TP53
2 12.52 AR BRCA2 ERBB2 ESR1 TP53
3
Show member pathways
12.39 BRCA2 ERBB2 ESR1 PGR TP53
4
Show member pathways
12.26 ATM BRCA2 ERCC4 ESR1 TP53
5
Show member pathways
11.97 ATM BRCA2 ERCC4 PALB2
6
Show member pathways
11.94 BRCA2 ERBB2 TP53
7
Show member pathways
11.93 ATM BRCA2 PALB2
8 11.9 ATM BRCA2 ERCC4 PHB TOP2A TP53
9 11.77 ATM ERBB2 TP53
10
Show member pathways
11.73 ERBB2 ESR1 PGR
11 11.65 BRCA2 ERCC4 PALB2
12
Show member pathways
11.61 AR ESR1 PGR
13
Show member pathways
11.55 ATM BRCA2 TP53
14 11.43 ATM ERBB2 TP53
15 11.32 ATM ERBB2 TOP2A TP53
16 11.29 AR ATM BRCA2 ESR1 PHB TP53
17
Show member pathways
10.91 ATM TP53
18 10.84 ATM TP53
19 10.62 CYP1A1 ESR1

GO Terms for Female Breast Cancer

Cellular components related to Female Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.73 AR ATM BRCA2 ERBB2 ERCC4 ESR1
2 protein complex GO:0043234 9.55 AR BRCA2 ESR1 TOP2A TP53
3 nuclear chromosome, telomeric region GO:0000784 9.43 ATM BRCA2 ERCC4
4 nucleoplasm GO:0005654 9.32 AR ATM BRCA2 ERCC4 ESR1 PALB2

Biological processes related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 AR ERBB2 PHB TP53
2 DNA repair GO:0006281 9.89 ATM BRCA2 ERCC4 PALB2
3 cell proliferation GO:0008283 9.8 AR BRCA2 CYP1A1 ERBB2 TP53
4 positive regulation of transcription, DNA-templated GO:0045893 9.8 AR BRCA2 ESR1 PHB TOX3 TP53
5 multicellular organism growth GO:0035264 9.69 AR ATM PALB2
6 steroid hormone mediated signaling pathway GO:0043401 9.65 AR ESR1 PGR
7 regulation of apoptotic process GO:0042981 9.65 ATM ESR1 PHB TOX3 TP53
8 nucleotide-excision repair GO:0006289 9.63 BRCA2 ERCC4 TP53
9 female gonad development GO:0008585 9.62 ATM BRCA2
10 response to X-ray GO:0010165 9.62 BRCA2 TP53
11 response to hyperoxia GO:0055093 9.61 CYP1A1 TP53
12 mammary gland alveolus development GO:0060749 9.6 AR ESR1
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.58 BRCA2 TP53
14 resolution of meiotic recombination intermediates GO:0000712 9.58 ERCC4 TOP2A
15 determination of adult lifespan GO:0008340 9.57 ATM TP53
16 replicative senescence GO:0090399 9.56 ATM TP53
17 inner cell mass cell proliferation GO:0001833 9.55 BRCA2 PALB2
18 positive regulation of transcription by RNA polymerase III GO:0045945 9.54 AR ERBB2
19 DNA synthesis involved in DNA repair GO:0000731 9.54 ATM BRCA2 PALB2
20 negative regulation of telomerase activity GO:0051974 9.52 ERCC4 TP53
21 progesterone receptor signaling pathway GO:0050847 9.49 PGR PHB
22 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.43 AR PGR
23 cellular response to DNA damage stimulus GO:0006974 9.43 ATM BRCA2 ERCC4 PALB2 TOP2A TP53
24 strand displacement GO:0000732 9.33 ATM BRCA2 PALB2
25 double-strand break repair via homologous recombination GO:0000724 8.92 ATM BRCA2 ERCC4 PALB2

Molecular functions related to Female Breast Cancer according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.95 BRCA2 ERBB2 ERCC4 ESR1 PGR TP53
2 DNA binding GO:0003677 9.81 AR ATM BRCA2 ERCC4 ESR1 PALB2
3 chromatin binding GO:0003682 9.77 AR ESR1 TOP2A TOX3 TP53
4 histone deacetylase binding GO:0042826 9.7 PHB TOP2A TP53
5 protein N-terminus binding GO:0047485 9.69 ATM ERCC4 TP53
6 ATPase binding GO:0051117 9.67 AR ESR1 PGR
7 steroid hormone receptor activity GO:0003707 9.61 AR ESR1 PGR
8 nuclear receptor activity GO:0004879 9.5 AR ESR1 PGR
9 steroid binding GO:0005496 9.43 AR ESR1 PGR
10 protein C-terminus binding GO:0008022 9.43 BRCA2 ERBB2 ERCC4 PHB TOP2A TP53
11 estrogen response element binding GO:0034056 9.4 ESR1 TOX3
12 enzyme binding GO:0019899 9.17 AR CYP1A1 ESR1 PGR PHB TOP2A
13 protein binding GO:0005515 10.27 AR ATM BRCA2 CYP1A1 ERBB2 ERCC4

Sources for Female Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....